Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
South Korea
· Delayed Price · Currency is KRW 79,000
+600 (0.77%)
Last updated: Apr 17, 2025
KRX:185750 Revenue
In the year 2024, Chong Kun Dang Pharmaceutical had annual revenue of 1.59T KRW, down -4.97%. Chong Kun Dang Pharmaceutical had revenue of 415.36B in the quarter ending December 31, 2024, a decrease of -17.69%.
Revenue
1,586.43B
Revenue Growth
-4.97%
P/S Ratio
0.65
Revenue / Employee
697.03M
Employees
2,276
Market Cap
1,036.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,586.43B | -82.97B | -4.97% |
| Dec 31, 2023 | 1,669.40B | 181.06B | 12.17% |
| Dec 31, 2022 | 1,488.34B | 144.79B | 10.78% |
| Dec 31, 2021 | 1,343.56B | 40.55B | 3.11% |
| Dec 31, 2020 | 1,303.01B | 223.67B | 20.72% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 68.13B |
| LigaChem Biosciences | 125.90B |
| PharmaResearch | 350.12B |